{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:45:34Z","timestamp":1789152334214,"version":"build-2803163510"},"reference-count":44,"publisher":"Walter de Gruyter GmbH","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jpem-2021-0389_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Some idiopathic short stature (ISS) patients may have varying degrees of insulin-like growth factor 1 (IGFI) deficiency. Others with growth hormone deficiency (GHD) (peak GH\u00a0&lt;\u00a07\u00a0ng\/dL after provocation) have normal IGFI levels. Do children with ISS or those with GHD with variable pretreatment IGFI standard deviation score (IGFISDS) have different IGFI and growth responses to recombinant human growth hormone (rhGH) therapy?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2021-0389_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We studied the effect of GH therapy (0.035\u20130.06\u00a0mg\/kg\/day) on linear growth and weight gain per day (WGPD) in children with ISS (n=13) and those with GHD (n=10) who have low pretreatment IGFISDS (IGF SDS\u00a0&lt;\u00a0\u22121.5) and compared them with age-matched prepubertal children with ISS (n=10) and GHD (n=17) who had normal pretreatment IGFISDS. An untreated group of children with ISS (n=12) served as a control group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2021-0389_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At presentation, the height standard deviation score (HtSDS) of children with ISS who had low pretreatment IGFISDS was significantly lower compared to the normal IGFI group. The age, body mass index (BMI), BMISDS, peak GH response to clonidine provocation and bone age did not differ between the two study groups. After 1\u00a0year of treatment with rhGH (0.035\u20130.06\u00a0mg\/kg\/day) IGFISDS increased significantly in both groups (p&lt;0.05). Both had significantly increased HtSDS (catch-up growth). The increase in the HtSDS and WGPD were significantly greater in the lower pretreatment IGFISDS group. The IGFSDS, BMISDS, HtSDS and difference between HtSDS and mid-parental HtSDS were significantly greater in the rhGH treated groups vs. the not treated group. In the GHD groups (normal and low IGFISDS), after 1\u00a0year of GH therapy (0.03\u20130.05\u00a0mg\/kg\/day), the HtSDS increased significantly in both, (p&lt;0.01). The WGPD and increment in BMI were significantly greater in children who had low pretreatment IGFISDS. There was a significant increase in the IGFSDS in the two treated groups (p&lt;0.05), however, the WGPD was greater in the pretreatment low IGFISDS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2021-0389_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IGFI deficiency represents a low anabolic state. Correction of IGFI level (through rhGH and\/or improved nutrition) in short children (ISS and GHD) was associated with increased linear growth and WGPD denoting significant effect on bone growth and muscle protein accretion.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jpem-2021-0389","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T22:11:06Z","timestamp":1626905466000},"page":"1263-1271","source":"Crossref","is-referenced-by-count":15,"title":["Growth response to growth hormone (GH) treatment in children with GH deficiency (GHD) and those with idiopathic short stature (ISS) based on their pretreatment insulin-like growth factor 1 (IGFI) levels and at diagnosis and IGFI increment on treatment"],"prefix":"10.1515","volume":"34","author":[{"given":"Ashraf","family":"Soliman","sequence":"first","affiliation":[{"name":"Department of Pediatrics , Hamad General Hospital , Doha , Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Rogol","sequence":"additional","affiliation":[{"name":"Department of Pediatrics , University of Virginia , Charlottesville , VA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohair","family":"Elsiddig","sequence":"additional","affiliation":[{"name":"Department of Pediatrics , Hamad General Hospital , Doha , Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Khalil","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy , Hamad General Hospital , Doha , Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Alaaraj","sequence":"additional","affiliation":[{"name":"Department of Pediatrics , Hamad General Hospital , Doha , Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawzia","family":"Alyafie","sequence":"additional","affiliation":[{"name":"Department of Pediatrics , Hamad General Hospital , Doha , Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Pediatrics , Hamad General Hospital , Doha , Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elawwa","sequence":"additional","affiliation":[{"name":"Department of Pediatrics , Alexandria University , Alexandria , Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2021,7,22]]},"reference":[{"key":"2023040101125224875_j_jpem-2021-0389_ref_001","doi-asserted-by":"crossref","unstructured":"Collett-Solberg, PF, Ambler, G, Backeljauw, PF, Bidlingmaier, M, Biller, BMK, Boguszewski, MCS, et al.. Diagnosis, genetics, and therapy of short stature in children: a Growth Hormone Research Society International Perspective. Horm Res Paediatr 2019;92:1\u201314. https:\/\/doi.org\/10.1159\/000502231.","DOI":"10.1159\/000502231"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_002","doi-asserted-by":"crossref","unstructured":"Park, P, Cohen, P. Insulin-like growth factor I (IGF-I) measurements in growth hormone (GH) therapy of idiopathic short stature (ISS). Growth Horm IGF Res 2005;15(A Suppl):S13\u201320. https:\/\/doi.org\/10.1016\/j.ghir.2005.06.011.","DOI":"10.1016\/j.ghir.2005.06.011"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_003","doi-asserted-by":"crossref","unstructured":"Smyczy\u0144ska, J, Smyczy\u0144ska, U, Hilczer, M, Stawerska, R, Lewi\u0144ski, A. Significance of direct confirmation of growth hormone insensitivity for the diagnosis of primary IGF-I deficiency. J Clin Med 2020;9:240.","DOI":"10.3390\/jcm9010240"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_004","doi-asserted-by":"crossref","unstructured":"\u015e\u0131klar, Z, Kocaay, P, \u00c7amtosun, E, \u0130sakoca, M, Hac\u0131hamdio\u011flu, B, Erdeve, S\u015e, et al.. The effect of recombinant growth hormone treatment in children with idiopathic short stature and low insulin-like growth factor-1 levels. J Clin Res Pediatr Endocrinol 2015;7:301\u20136. https:\/\/doi.org\/10.4274\/jcrpe.2111.","DOI":"10.4274\/jcrpe.2111"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_005","doi-asserted-by":"crossref","unstructured":"Blum, WF, Alherbish, A, Alsagheir, A, El Awwa, A, Kaplan, W, Koledova, E, et al.. The growth hormone-insulin-like growth factor-I axis in the diagnosis and treatment of growth disorders. Endocr Connect 2018;7:R212-22. https:\/\/doi.org\/10.1530\/ec-18-0099.","DOI":"10.1530\/EC-18-0099"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_006","doi-asserted-by":"crossref","unstructured":"Savage, MO, Burren, CP, Rosenfeld, RG. The continuum of growth hormone-IGF-I axis defects causing short stature: diagnostic and therapeutic challenges. Clin Endocrinol 2010;72:721\u20138. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03775.x.","DOI":"10.1111\/j.1365-2265.2009.03775.x"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_007","doi-asserted-by":"crossref","unstructured":"Ranke, MB, Lindberg, A. Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables. J Clin Endocrinol Metab 2010;95:1229\u201337. https:\/\/doi.org\/10.1210\/jc.2009-1471.","DOI":"10.1210\/jc.2009-1471"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_008","doi-asserted-by":"crossref","unstructured":"Bakker, B, Frane, J, Anhalt, H, Lippe, B, Rosenfeld, RG. Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children. J Clin Endocrinol Metab 2008;93:352\u20137. https:\/\/doi.org\/10.1210\/jc.2007-1581.","DOI":"10.1210\/jc.2007-1581"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_009","doi-asserted-by":"crossref","unstructured":"Ranke, MB, Lindberg, A, International Board. Prediction models for short children born small for gestational age (SGA) covering the total growth phase. Analyses based on data from KIGS (Pfizer International Growth Database). BMC Med Inf Decis Making 2011;11:38. https:\/\/doi.org\/10.1186\/1472-6947-11-38.","DOI":"10.1186\/1472-6947-11-38"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_010","doi-asserted-by":"crossref","unstructured":"Cohen, P, Rogol, AD, Howard, CP, Bright, GM, Kappelgaard, AM, Rosenfeld, RG, American Norditropin Study Group. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. J Clin Endocrinol Metab 2007;92:2480\u20136. https:\/\/doi.org\/10.1210\/jc.2007-0204.","DOI":"10.1210\/jc.2007-0204"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_011","doi-asserted-by":"crossref","unstructured":"Cohen, P, Weng, W, Rogol, AD, Rosenfeld, RG, Kappelgaard, AM, Germak, J. Dose-sparing and safety-enhancing effects of an IGF-I-based dosing regimen in short children treated with growth hormone in a 2-year randomized controlled trial: therapeutic and pharmacoeconomic considerations. Clin Endocrinol 2014;81:71\u20136. https:\/\/doi.org\/10.1111\/cen.12408.","DOI":"10.1111\/cen.12408"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_012","doi-asserted-by":"crossref","unstructured":"Lennartsson, O, Nilsson, O, Lodefalk, M. Discordance between stimulated and spontaneous growth hormone levels in short children is dependent on cut-off level and partly explained by refractoriness. Front Endocrinol 2020;11:584906. https:\/\/doi.org\/10.3389\/fendo.2020.584906.","DOI":"10.3389\/fendo.2020.584906"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_013","doi-asserted-by":"crossref","unstructured":"Royston, P, Wright, EM. A method for estimating age-specific reference intervals based on fractional polynomials and exponential transformation. J Roy Stat Soc Stat Soc 1998;161:79\u2013101. https:\/\/doi.org\/10.1111\/1467-985x.00091.","DOI":"10.1111\/1467-985X.00091"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_014","doi-asserted-by":"crossref","unstructured":"Chanson, P, Arnoux, A, Mavromati, M, Brailly-Tabard, S, Massart, C, Young, J, VARIETE Investigators, et al.. Reference values for IGF-I serum concentrations: comparison of six immunoassays. J Clin Endocrinol Metab 2016;101:3450\u20138. https:\/\/doi.org\/10.1210\/jc.2016-1257.","DOI":"10.1210\/jc.2016-1257"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_015","doi-asserted-by":"crossref","unstructured":"Greulich, W, Pyle, I. Radiographic atlas of skeletal development\u00a0of the hand and wrist. London: Stanford University Press; 1959.","DOI":"10.1097\/00000441-195909000-00030"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_016","doi-asserted-by":"crossref","unstructured":"Cohen, P, Rogol, AD, Weng, W, Kappelgaard, AM, Rosenfeld, RG, Germak, J, American Norditropin Study Group. Efficacy of IGF-based growth hormone (GH) dosing in nonGH-deficient (nonGHD) short stature children with low IGF-I is not related to basal IGF-I levels. Clin Endocrinol 2013;78:405\u201314. https:\/\/doi.org\/10.1111\/cen.12014.","DOI":"10.1111\/cen.12014"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_017","doi-asserted-by":"crossref","unstructured":"van der Steen, M, Hokken-Koelega, AC. Growth and metabolism in children born small for gestational age. Endocrinol Metab Clin N Am 2016;45:283\u201394. https:\/\/doi.org\/10.1016\/j.ecl.2016.01.008.","DOI":"10.1016\/j.ecl.2016.01.008"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_018","doi-asserted-by":"crossref","unstructured":"de Zegher, F, Hokken-Koelega, A. Growth hormone therapy for children born small for gestational age: height gain is less dose dependent over the long term than over the short term. Pediatrics 2005;115:e458\u201362. https:\/\/doi.org\/10.1542\/peds.2004-1934.","DOI":"10.1542\/peds.2004-1934"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_019","doi-asserted-by":"crossref","unstructured":"de Zegher, F, Du Caju, MV, Heinrichs, C, Maes, M, De Schepper, J, Craen, M, et al.. Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: results over 6 years. J Clin Endocrinol Metab 1999;84:1558\u201361. https:\/\/doi.org\/10.1210\/jcem.84.5.5697.","DOI":"10.1210\/jcem.84.5.5697"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_020","doi-asserted-by":"crossref","unstructured":"Kaplowitz, PB, Rundle, AC, Blethen, SL. Weight relative to height before and during growth hormone therapy in prepubertal children. Horm Metab Res 1998;30:565\u20139. https:\/\/doi.org\/10.1055\/s-2007-978934.","DOI":"10.1055\/s-2007-978934"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_021","doi-asserted-by":"crossref","unstructured":"Rapaport, R, Saenger, P, Wajnrajch, MP, Pfizer SGA Collaborative Study Group. Predictors of first-year growth response to a fixed-dose growth hormone treatment in children born small for gestational age: results of an open-label, multicenter trial in the United States. J Pediatr Endocrinol Metab 2008;21:411\u201322. https:\/\/doi.org\/10.1515\/jpem.2008.21.5.411.","DOI":"10.1515\/JPEM.2008.21.5.411"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_022","doi-asserted-by":"crossref","unstructured":"Reinehr, T, Lindberg, A, Koltowska-H\u00e4ggstr\u00f6m, M, Ranke, M. Is growth hormone treatment in children associated with weight gain?\u00a0\u2013 longitudinal analysis of KIGS data. Clin Endocrinol 2014;81:721\u20136. https:\/\/doi.org\/10.1111\/cen.12464.","DOI":"10.1111\/cen.12464"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_023","doi-asserted-by":"crossref","unstructured":"Esen, F, Demirel, D, Tepe, OK, Koc, N. The association between growth response to growth hormone and baseline body composition of children with growth hormone deficiency. Growth Hormone IGF Res 2013;23:196\u20139. https:\/\/doi.org\/10.1016\/j.ghir.2013.07.001.","DOI":"10.1016\/j.ghir.2013.07.001"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_024","doi-asserted-by":"crossref","unstructured":"Mukherjee, RDM, Shalet, SM. Impact of growth hormone status on body composition and the skeleton. Horm Res 2004;62(3 Suppl):35\u201341. https:\/\/doi.org\/10.1159\/000080497.","DOI":"10.1159\/000080497"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_025","doi-asserted-by":"crossref","unstructured":"Khadilkar, V, Ekbote, V, Kajale, N, Khadilkar, A, Chiplonkar, S, Kinare, A. Effect of one-year growth hormone therapy on body composition and cardio-metabolic risk in Indian children with growth hormone deficiency. Endocr Res 2014;39:73\u20138. https:\/\/doi.org\/10.3109\/07435800.2013.828742.","DOI":"10.3109\/07435800.2013.828742"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_026","doi-asserted-by":"crossref","unstructured":"Ciresi, A, Amato, MC, Criscimanna, A, Mattina, A, Vetro, C, Galluzzo, A, et al.. Metabolic parameters and adipokine profile during GH replacement therapy in children with GH deficiency. Eur J Endocrinol 2007;156:353\u201360. https:\/\/doi.org\/10.1530\/eje.1.02343.","DOI":"10.1530\/eje.1.02343"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_027","doi-asserted-by":"crossref","unstructured":"Matusik, P, Klesiewicz, M, Klos, K, Stasiulewicz, M, Barylak, A, Nazarkiewicz, P, et al.. Baseline body composition in prepubertal short stature children with severe and moderate growth hormone deficiency. Int J Endocrinol 2016;2016:4563721. https:\/\/doi.org\/10.1155\/2016\/4563721.","DOI":"10.1155\/2016\/4563721"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_028","doi-asserted-by":"crossref","unstructured":"Roemmich, JN, Huerta, MG, Sundaresan, SM, Rogol, AD. Alterations in body composition and fat distribution in growth hormone-deficient prepubertal children during growth hormone therapy. Metabolism 2001;50:537\u201347. https:\/\/doi.org\/10.1053\/meta.2001.22510.","DOI":"10.1053\/meta.2001.22510"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_029","doi-asserted-by":"crossref","unstructured":"H\u00f6gler, W, Briody, J, Moore, B, Lu, PW, Cowell, CT. Effect of growth hormone therapy and puberty on bone and body composition in children with idiopathic short stature and growth hormone deficiency. Bone 2005;37:642\u201350. https:\/\/doi.org\/10.1016\/j.bone.2005.06.012.","DOI":"10.1016\/j.bone.2005.06.012"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_030","doi-asserted-by":"crossref","unstructured":"Hawcutt, DB, Bellis, J, Price, V, Povall, A, Newland, P, Richardson, P, et al.. Growth hormone prescribing and initial BMI SDS: increased biochemical adverse effects and costs in obese children without additional gain in height. PLoS One 2017;12:e0181567. https:\/\/doi.org\/10.1371\/journal.pone.0181567.","DOI":"10.1371\/journal.pone.0181567"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_031","doi-asserted-by":"crossref","unstructured":"Yackobovitch-Gavan, M, Gat-Yablonski, G, Shtaif, B, Hadani, S, Abargil, S, Phillip, M, et al.. Growth hormone therapy in children with idiopathic short stature - the effect on appetite and appetite-regulating hormones: a pilot study. Endocr Res 2019;44:16\u201326. https:\/\/doi.org\/10.1080\/07435800.2018.1493598.","DOI":"10.1080\/07435800.2018.1493598"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_032","doi-asserted-by":"crossref","unstructured":"Fontana, L, Weiss, EP, Villareal, DT, Klein, S, Holloszy, JO. Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans. Aging Cell 2008;7:681\u20137. https:\/\/doi.org\/10.1111\/j.1474-9726.2008.00417.x.","DOI":"10.1111\/j.1474-9726.2008.00417.x"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_033","doi-asserted-by":"crossref","unstructured":"Underwood, LE, Thissen, JP, Lemozy, S, Ketelslegers, JM, Clemmons, DR. Hormonal and nutritional regulation of IGF-I and its binding proteins. Horm Res 1994;42:145\u201351. https:\/\/doi.org\/10.1159\/000184187.","DOI":"10.1159\/000184187"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_034","doi-asserted-by":"crossref","unstructured":"Yakar, S, Liu, JL, Stannard, B, Butler, A, Accili, D, Sauer, B, et al.. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A 1999;96:7324\u20139. https:\/\/doi.org\/10.1073\/pnas.96.13.7324.","DOI":"10.1073\/pnas.96.13.7324"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_035","doi-asserted-by":"crossref","unstructured":"Clemmons, DR. Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol Metab Clin N Am 2012;41:425. https:\/\/doi.org\/10.1016\/j.ecl.2012.04.017.","DOI":"10.1016\/j.ecl.2012.04.017"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_036","doi-asserted-by":"crossref","unstructured":"Bortvedt, SF, Lund, PK. Insulin-like growth factor 1: common mediator of multiple enterotrophic hormones and growth factors. Curr Opin Gastroenterol 2012;28:89\u201398. https:\/\/doi.org\/10.1097\/mog.0b013e32835004c6.","DOI":"10.1097\/MOG.0b013e32835004c6"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_037","doi-asserted-by":"crossref","unstructured":"Gillingham, MB, Dahly, EM, Murali, SG, Ney, DM. IGF-I treatment facilitates transition from parenteral to enteral nutrition in rats with short bowel syndrome. Am J Physiol Regul Integr Comp Physiol 2003;284:R363\u201371. https:\/\/doi.org\/10.1152\/ajpregu.00247.2002.","DOI":"10.1152\/ajpregu.00247.2002"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_038","doi-asserted-by":"crossref","unstructured":"Houle, V, Park, Y, Laswell, S, Freund, GG, Dudley, MA, Donovan, SM. Investigation of three doses of oral insulin-like growth factor-I on jejunal lactase phlorizin hydrolase activity and gene expression and enterocyte proliferation and migration in piglets. Pediatr Res 2000;48:497\u2013503. https:\/\/doi.org\/10.1203\/00006450-200010000-00013.","DOI":"10.1203\/00006450-200010000-00013"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_039","doi-asserted-by":"crossref","unstructured":"Hong, H, Cui, ZZ, Zhu, L, Fu, SP, Rossi, M, Cui, YH, et al.. Central IGF1 improves glucose tolerance and insulin sensitivity in mice. Nutr Diabetes 2017;7:2. https:\/\/doi.org\/10.1038\/s41387-017-0002-0.","DOI":"10.1038\/s41387-017-0002-0"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_040","unstructured":"Wang, DD, Sun, M, Wang, X, Cheng, YY. Changes in serum levels of IGF-1, ghrelin and nesfatin-1 and clinical significance after treatment with recombinant human growth hormone in children with idiopathic short stature. J Biol Regul Homeost Agents 2019;33:1759\u201363. https:\/\/doi.org\/10.23812\/19-231-L."},{"key":"2023040101125224875_j_jpem-2021-0389_ref_041","doi-asserted-by":"crossref","unstructured":"Oh-i, S, Shimizu, H, Satoh, T, Okada, S, Adachi, S, Inoue, K, et al.. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006;443:709\u201312. https:\/\/doi.org\/10.1038\/nature05162.","DOI":"10.1038\/nature05162"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_042","doi-asserted-by":"crossref","unstructured":"V\u00e9lez, EJ, Unniappan, S. Nesfatin\u20131 and nesfatin\u20131\u2013like peptide suppress growth hormone synthesis via the AC\/PKA\/CREB pathway in mammalian somatotrophs. Sci Rep 2020;10:16686. https:\/\/doi.org\/10.1038\/s41598-020-73840-4.","DOI":"10.1038\/s41598-020-73840-4"},{"key":"2023040101125224875_j_jpem-2021-0389_ref_043","unstructured":"Carrel, AL, Allen, DB. Effects of growth hormone on adipose tissue. J Pediatr Endocrinol Metab 2000;13:1003\u20139."},{"key":"2023040101125224875_j_jpem-2021-0389_ref_044","doi-asserted-by":"crossref","unstructured":"Chikani, V, Ho, KK. Action of GH on skeletal muscle function: molecular and metabolic mechanisms. J Mol Endocrinol 2013;52:R107\u201323. https:\/\/doi.org\/10.1530\/JME-13-0208.","DOI":"10.1530\/JME-13-0208"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2021-0389\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2021-0389\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T14:59:55Z","timestamp":1680361195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2021-0389\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,22]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,7,20]]},"published-print":{"date-parts":[[2021,10,26]]}},"alternative-id":["10.1515\/jpem-2021-0389"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2021-0389","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,22]]}}}